-The Hindu     Until activists and patients question approaches to prevention, diagnosis and treatment, TB will continue to plague us Tuberculosis in India is big: 2.3 million cases, 30,000 deaths, a million missing patients. These terrifying numbers remind us of a continuing crisis - when every TB death is preventable. Behind these numbers are innumerable unheard stories of human suffering - of misdiagnosis, inappropriate treatment and lack of access to care resulting in...

-The Hindu Differences over intellectual property rights (IPRs) have emerged as a strong undercurrent in India's economic relations with the U.S. The attempt by the influential pharmaceutical lobby to stymie India's efforts to ensure the supply of medicines at affordable rates without violating existing treaty commitments, requires a principled response from New Delhi. At the core of the issue is what Columbia University Professor Arvind Panagariya calls "the hijacking of...

-The Business Standard The Congress party's suggested right to health, if implemented, would be a game-changer This is the season for party manifestos with their vague and quite unexciting promises. But in this sea of platitudes, sometimes something stands out that is worth talking about, because, if implemented, it would be a game-changer. For me this is the reported inclusion of the right to health in the Congress party's manifesto. It is well...

-The Business Standard The recent US-India friction over trade is being driven by Big Pharma Apart from the deterioration of the business environment generally, which impacts both domestic and foreign investors, retrospective taxation has figured most prominently in the media as the principal cause of growing scepticism among foreign investors. Entirely missing from the discourse has been an equally potent factor with wholly foreign origins: the hijacking of the economic policy...

-The Indian Express India's role in pharmaceutical patent wars has broadened access to healthcare. Recently, there were rumours that the United States Trade Representative (USTR) was getting ready to announce "trade enforcement actions" or sanctions against India over its intellectual property rights regime. The Obama administration has been under pressure from the US Chamber of Commerce and lobby groups, like the Pharmaceutical Research and Manufacturers of America, to take a tough stance...